Travere Therapeutics Inc. research snapshot
TVTX AI stock analysis currently reads Travere Therapeutics as a high-reward commercial-stage rare kidney disease biopharmaceutical company that turned its FILSPARI (sparsentan) approval into a rapidly growing revenue stream but still reports GAAP net losses. At the July 12, 2026 cutoff, the latest verified close used here was $56.59, market capitalization was about $5.26 billion, and the main question was whether FILSPARI revenue growth, pipeline expansion through the Everest Medicines civorebrutinib licensing deal, and eventual profitability can sustain the premium 11x price-to-sales valuation. This is informational research and not investment advice.
Current price
$56.59
Market cap
$5.26 billion
AI score
62 / 100
Rating
High-reward commercial-stage biotech with execution risk
Trend status
Strong uptrend near 52-week highs after 247% yearly gain
Data cutoff (updated weekly)
July 12, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Travere sells targeted rare kidney disease therapies. FILSPARI is the first non-immunosuppressive therapy approved for IgA nephropathy, a large underserved market. Revenue is growing but the company is not yet GAAP profitable. | Medium |
| Moat | The moat is based on FILSPARI first-in-class status in IgAN, orphan drug exclusivity, patent protection into the 2030s, and specialty distribution. Durability depends on whether follow-on competitors can match or beat the efficacy-safety profile. | Medium |
| Management | CEO Eric Dube and the team have executed the FILSPARI launch and recently signed the Everest Medicines licensing deal for civorebrutinib. The planned 2027 retirement of the chief research officer creates a key transition risk. | Medium |
| Financial trend | Annual revenue reached $490.73 million in the most recent fiscal year. Q1 2026 revenue was $127.20 million, up significantly year over year but slightly below the $136.23 million consensus. GAAP net loss was $50.26 million for the fiscal year. | Medium-high |
| Valuation | The stock trades at about 11x price-to-sales and 55x book value. With negative GAAP EPS, conventional PE-based valuation is not applicable. The premium P/S multiple assumes continued rapid revenue growth and a clear path to profitability. | Medium |
| Technical trend | TVTX is in a strong uptrend from its 52-week low of $15.03, trading near the $56 to $60 zone. The stock is up 247% over one year and has pulled back about 6% from the 52-week high of $60.10. | Medium-high |
| Risk level | Key risks are FILSPARI revenue concentration, IgAN competition (Tarpeyo, iptacopan, atrasentan), pipeline setbacks, GAAP unprofitability, reimbursement changes, shareholder dilution, and the high beta of 2.14 amplifying downside moves. | Medium-high |
| AI confidence | Medium-high confidence for the commercial-stage facts, revenue data, analyst consensus, market cap math, and major risk categories. Lower confidence for pipeline probability-adjusted valuation and long-term market share outcomes. | Medium-high data confidence |
| Investment certainty | Low to medium certainty. FILSPARI is a real product with growing revenue, but the stock price already reflects aggressive expectations. Execution on pipeline, profitability, and competitive positioning will determine whether the current valuation is justified. | Low to medium |
TVTX AI stock forecast
The TVTX AI stock forecast uses scenario ranges around the $56.59 cutoff price. It does not claim that AI can predict a specific future price. The bullish case requires FILSPARI to capture a leading share of the IgAN market, pipeline milestones to add value, and the company to reach GAAP profitability. The base case assumes steady FILSPARI growth with pipeline optionality. The bearish case assumes competitive erosion or commercial disappointments.
$90 to $130
More likely if FILSPARI achieves 30%+ IgAN patient share, the civorebrutinib licensing deal generates clinical and commercial upside, the company reaches sustained GAAP profitability, and investors assign a 15x to 20x forward P/S multiple.
$45 to $70
More likely if FILSPARI grows revenue at 20% to 30% annually, pipeline progresses but does not add near-term revenue, GAAP losses narrow, and the stock trades in a 8x to 12x P/S range.
$20 to $38
More likely if FILSPARI faces unexpected competition or access barriers, revenue growth decelerates sharply, pipeline candidates fail, and the market re-rates the stock toward a 4x to 6x P/S multiple.
TVTX AI technical analysis
TVTX AI technical analysis starts from the $56.59 close used for this July 12 static page. Public technical sources showed the stock above its key moving averages after a strong multi-month rally. RSI was near 70, suggesting overbought conditions. Because this page does not fetch request-time market data, traders should confirm levels on a live chart before acting.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $56.59 | Latest verified close used for this page as of the July 12, 2026 data cutoff. |
| Near support | $46 to $50 | Support zone near the 20-day and 50-day moving average area. The stock gapped up from this zone in mid-June 2026. |
| Secondary support | $28 to $32 | The prior resistance-turned-support zone from the April-May 2026 consolidation. A break below would signal a trend change. |
| Near resistance | $58 to $60 | The 52-week high zone at $60.10. Breakout above this level with volume could open the path to price discovery. |
| 50-day moving average | About $46 to $48 | TVTX was trading above the 50-day moving average based on public technical sources around the cutoff. |
| 200-day moving average | About $30 to $32 | The 200-day moving average is well below the current price, confirming the strong long-term uptrend. |
| Momentum | RSI near 70, stretched | The 14-day RSI was approaching overbought territory. Short-term oscillators suggested the rally may be extended near the 52-week high. |
| Volume | About 2.9 million shares daily | The July 10 volume snapshot was above the 30-day average of 691,000 options contracts, indicating active trading interest. |
| Volatility | Beta 2.14, IV 74.5% | TVTX has a one-year beta of 2.14 and implied volatility of 74.5%, making it a high-volatility name. Position sizing should account for large daily swings. |
| Invalidation | Close below $46, then $32 | A close below the 50-day area weakens the near-term bullish setup. A break below the 200-day area would challenge the long-term trend. |
TVTX AI trading strategy
The TVTX AI trading strategy is a rules-based framework, not personalized advice. It combines filing-backed commercial evidence, technical confirmation, position sizing, and clear invalidation levels. Given the high beta of 2.14 and implied volatility above 74%, position sizes should be smaller than for lower-volatility names.
Look for TVTX to hold above the $46 to $50 support zone and break above the $60.10 52-week high with above-average volume. An earnings beat or pipeline news could provide the catalyst.
A daily close below $46 or a failed breakout from the $58 to $60 resistance zone with rising volume should reduce confidence in the continuation setup.
If TVTX pulls back toward $46 to $50 without breaking the commercial thesis, look for price stabilization and positive catalyst timing before considering re-entry.
Do not average down solely because the stock has a Strong Buy consensus. Monitor FILSPARI prescription trends and quarterly revenue reports for fundamental confirmation.
Track Q2 2026 earnings (estimated around August 5), FILSPARI revenue growth rate, new prescriber trends, IgAN competitor news and market updates, and pipeline progress for civorebrutinib and other candidates.
Reduce position ahead of binary events like earnings or clinical data readouts if position size is larger than risk tolerance allows.
Investment research summary
Travere Therapeutics develops and commercializes therapies for rare kidney diseases. FILSPARI (sparsentan) is the first and only non-immunosuppressive treatment approved for IgA nephropathy, a chronic kidney disease affecting an estimated 130,000 to 500,000 patients in the US alone.
FILSPARI holds first-in-class and orphan drug status in IgAN, with US patent protection extending into the 2030s. The rare disease market creates high prescriber and patient switching costs. Competitors including Novartis (iptacopan) and Chinook (atrasentan) are in late-stage development and could narrow the moat.
The thesis can fail if FILSPARI revenue growth slows from competitive pressure or payer restrictions, pipeline candidates including civorebrutinib fail in clinical trials, the company cannot reach GAAP profitability and needs dilutive financing, or the stock gives back gains in a biotech sector downturn.
CEO Eric Dube has led the FILSPARI launch and recently signed a strategic licensing deal with Everest Medicines for civorebrutinib valued at $47.5 million upfront plus milestones. The planned retirement of Chief Research Officer William Rote in early 2027 is a key organizational transition to monitor.
Rare kidney disease is a growing therapeutic area with high unmet need, regulatory incentives including orphan drug designation and accelerated approval pathways, and increasing pharmaceutical industry interest. The IgAN market alone is estimated at $5 billion to $10 billion globally.
At about 11x price-to-sales and negative GAAP earnings, TVTX prices in continued rapid revenue growth and eventual profitability. The current level offers limited margin of safety if growth disappoints. A fair entry depends on conviction in FILSPARI market share and pipeline probability.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| TVTX price | $56.59 close on July 10, 2026 | Barchart and TradingView quote snapshots | July 12, 2026 |
| Market capitalization | $5.26 billion, verified as $56.59 x 92,993,000 shares | financial_rigor.py market cap verification and Barchart | July 12, 2026 |
| Annual revenue (FY) | $490.73 million | Barchart and TradingView financial summaries | July 12, 2026 |
| Annual net income (FY, GAAP) | -$50.26 million | TradingView financial summary | July 12, 2026 |
| Q1 2026 revenue | $127.20 million vs $136.23 million consensus | TradingView earnings data | July 12, 2026 |
| EPS (TTM) | -$0.50 | TradingView financial summary | July 12, 2026 |
| Shares outstanding | 92.99 million | Barchart fundamentals | July 12, 2026 |
| Cash and equivalents | Not publicly verified - annual report needed | SEC filings search required | Not verified |
| Analyst consensus | Strong Buy, 16 analysts, target range $43 to $70 | Barchart analyst ratings | July 12, 2026 |
| 52-week range | $15.03 to $60.10 | Barchart price performance | July 12, 2026 |
| Moving averages | 50-day MA about $46 to $48, 200-day MA about $30 to $32 | Barchart technical snapshots | July 12, 2026 |
| Valuation math | 11.08x P/S, 54.94x P/B, 161.69x P/FCF, negative P/E from financial_rigor.py | financial_rigor.py valuation verification | July 12, 2026 |
This TVTX AI stock analysis is an informational tool for research and education only. It is not investment advice, a recommendation, or a guarantee of future performance. Forecast ranges are scenarios based on available data as of July 12, 2026 and can be wrong. Investing in biotech stocks carries significant risks including clinical trial failures, regulatory setbacks, and competitive dynamics.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
